NCT06426992 Clinical Effectiveness of Microwave Ablation Using Starwave Microwave Generator for Hepatic Malignancies
| NCT ID | NCT06426992 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Seoul National University Hospital |
| Condition | Liver Malignant Tumors |
| Study Type | INTERVENTIONAL |
| Enrollment | 128 participants |
| Start Date | 2024-04-30 |
| Primary Completion | 2026-08-30 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 128 participants in total. It began in 2024-04-30 with a primary completion date of 2026-08-30.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The purpose of this study is to determine the technical success rate of creating a safety margin of 5 mm or more including the tumor by performing image-guided percutaneous microwave thermal therapy using a microwave generator and antenna developed by StarMed for the treatment of small liver cancer and the 1-year local recurrence rate based on follow-up imaging tests.
Eligibility Criteria
Inclusion Criteria: * Child-Pugh Class A or B * Patients with suspected hepatocellular carcinoma or residual/recurrent hepatocellular carcinoma of 4 cm or less on MDCT, CEUS, or MRI performed within the last 60 days or Patients with suspected metastatic liver cancer of 4 cm or less on MDCT, CEUS, or MRI performed within the last 60 days, for whom microwave thermal ablation is being considered Exclusion Criteria: * In cases where there are three or more malignant liver tumors * When the maximum size of the tumor exceeds 4 cm * Diffuse infiltrative type of cancer with unclear tumor boundaries * When the tumor is adhered to the central hepatic portal vein, hepatic vein, or bile duct by 5 mm or more * Severe liver failure (Child-Pugh Class C) * In cases of vascular invasion by malignant liver tumors * Severe coagulopathy (platelet count below 50,000/mm³ or INR prolonged by more than 50%) * In cases of multiple extrahepatic metastases * Situations where it is highly unlikely to obtain appropriate data for research purposes
Contact & Investigator
Frequently Asked Questions
Who can join the NCT06426992 clinical trial?
This trial is open to participants of all sexes, aged 20 Years or older, up to 85 Years, studying Liver Malignant Tumors. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06426992 currently recruiting?
Yes, NCT06426992 is actively recruiting participants. Contact the research team at redlion55@naver.com for enrollment information.
Where is the NCT06426992 trial being conducted?
This trial is being conducted at Seoul, South Korea.
Who is sponsoring the NCT06426992 clinical trial?
NCT06426992 is sponsored by Seoul National University Hospital. The trial plans to enroll 128 participants.